> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-56/
- Published: 2022-01-02T12:00:00.000Z
- Updated: 2026-09-14T17:26:24.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5137087

**UroGen Pharma** has licensed to **Allergan** the worldwide rights to UroGen’s RTGel delivery system technology for use with neurotoxins. RTGel has thermo-sensitive properties that enable it to convert from a liquid state when cold, into a gel once it reaches body temperature, which allows increased “residence time” for drugs mixed with the gel and instilled in the bladder.

**Hanmi Pharmaceutical Co.** has entered into an exclusive development and license agreement with **Genentech** to develop and commercialize Hanmi’s pan-RAF inhibitor, HM95573 which is currently in Phase 1 clinical development. Hanmi will receive an initial upfront payment of $80 million and is eligible to receive payments based on achievement of certain predetermined development, regulatory and commercialization milestones totaling up to $830 million.

Contract manufacturer **Tecomet Inc.** has acquired **Mountainside Medical**, a Boulder, CO maker of medical device components and surgical devices. Mountainside Medical makes instruments for minimally invasive surgeries as well as medical device components for clients, and it has a pipeline of new products in development.

**TriFusion Devices**, a 3D printing company that focuses on health care and sports equipment, has acquired **Essentium Materials LLC**, which focuses on fusing 3D printed parts to biomedical devices. Essentium’s technology will be used for prosthetic devices, sporting equipment and military devices.